Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by TheBearInTheWoodson Jul 06, 2021 9:21am
112 Views
Post# 33498199

RE:Shocker - Will Not Advance Ifenprodil into Phase 3

RE:Shocker - Will Not Advance Ifenprodil into Phase 3 I sincerely hope that a lot of people that were new to the market and did not understand the CSE learnt a lot from this play. This happens all the time and when you call it out , you get called a basher etc by those exploiting retail investors or those falling in love.

Well done by management though, they pumped a stock worth a nickel and took it to .56, raised enough money to pay salaries and keep the lights on. They pivoted to Covid and made some questionable claims and statements that could lead to claims if it effected the wrong person, they pivoted to DMT to start this process again but with no luck.

Never go all in on a play where there is no insider ownership, where the chief science officer quits in the middle of a phase II, where management has such little regard for the shareholders that it raises at .35 when trading at .56.

life is filled with moments to learn from ,

beat of luck 
<< Previous
Bullboard Posts
Next >>